Research & Development: Page 16

  • Dr. Marc Conant, chief medical officer, American Gene Technologies
    Image attribution tooltip
    Permission granted by Natalie Ferguson/American Gene Technologies
    Image attribution tooltip
    Profile

    HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

    From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

    By • March 5, 2024
  • The staff of CG Oncology rings the opening bell at Nasdaq as confetti falls.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc.
    Image attribution tooltip

    Biotech IPOs heated up to start 2024. Will the surge last?

    Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead. 

    By Gwendolyn Wu , Ben Fidler • March 5, 2024
  • cancer R&D Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Oncology R&D

    Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

    By PharmaVoice staff
  • lots of colorful pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Black Diamond looks to outwit cancer mutations

    Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

    By Kelly Bilodeau • March 4, 2024
  • Neuron ALS
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    By • Feb. 29, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a top scientist and Moderna co-founder change the CRO game?

    From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

    By • Feb. 28, 2024
  • Gianluca Pirozzi header
    Image attribution tooltip
    Permission granted by Gianluca Pirozzi
    Image attribution tooltip
    Profile

    Behind a big-name rare disease biotech, an exec draws from personal experience

    The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

    By Alexandra Pecci • Feb. 27, 2024
  • blue dosing pen for semaglutide
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic for liver disease? Weight loss drugs could have even more to offer

    GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

    By Kelly Bilodeau • Feb. 26, 2024
  • Moderna company name on side of building
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Q&A

    For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

    Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

    By Amy Baxter • Feb. 23, 2024
  • chemist in lab with dropper
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    4 biotechs to watch in 2024

    A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

    By Alexandra Pecci • Feb. 21, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • IoT and AI design
    Image attribution tooltip
    Permission granted by Avenga
    Image attribution tooltip
    Sponsored by Avenga

    Value and potential of IoT and AI for chronic diseases treatment

    A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

    By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024
  • paper pie chart hand placing a piece
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma CFOs need R&D vigilance in tough economic times

    Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

    By Amy Baxter • Feb. 16, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By • Feb. 15, 2024
  • pill loading
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • Dr. Robert Califf, FDA commissioner, speaking at a podium with hands up
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    FDA inches closer to defining its regulatory role in AI

    Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

    By Amy Baxter • Feb. 12, 2024
  • Brain MRI
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Yoshi Shitaka
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas’ science chief on the leap into new technologies

    After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

    By • Feb. 9, 2024
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

    While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

    By • Feb. 8, 2024
  • rocket ship blasting into space with stars and clouds
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vaxxinity is brewing up meds for a spacefaring future

    The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

    By Kelly Bilodeau • Feb. 5, 2024
  • Dr. Marcel van den Brink, President, City of Hope Cancer Center
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

    The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.  

    By • Jan. 31, 2024
  • AZ vaccine
    Image attribution tooltip
    Ricardo Ceppi via Getty Images
    Image attribution tooltip

    Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

    Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

    By Alexandra Pecci • Jan. 30, 2024
  • neck pain stock
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tonix closes in on the first new fibromyalgia drug in more than a decade

    In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

    By Kelly Bilodeau • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By • Jan. 26, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By • Jan. 25, 2024